Riskpilot← Back to searchSign inGet full accessNORMORS AS
ASActiveOrg 980537595Myklebust 225, 6082 GurskenWholesale of pharmaceutical and medical goods · NACE 4646Est. 19985 employees
Revenue 2025
NOK 10,3M
-8% vs 2024
EBITDA margin
39.6%
-21% vs 2024
Equity ratio
50.4%
Financial strength
Net profit 2025
NOK 3,9M
-27% vs 2024
| Revenue | NOK 10,3M | -8% |
| EBITDA | NOK 4,1M | -21% |
| Net profit | NOK 3,9M | -27% |
| Total assets | NOK 10,4M | -7% |
| Equity | NOK 5,3M | -9% |
| Employees | 5 | — |
Legal name
NORMORS AS
Org number
980537595
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
28. desember 1998
Share capital
NOK 133 397
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Address
Myklebust 225, 6082 Gursken
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 8 868 | 8 461 | 9 924 | 11 224 | 10 300 |
| Staff expenses | −1 952 | −2 006 | −2 431 | −3 131 | −3 377 |
| EBITDA | 4 223 | 3 770 | 4 699 | 5 162 | 4 074 |
| Depreciation & amort. | −47 | −47 | −176 | −187 | −201 |
| EBIT | 4 176 | 3 723 | 4 523 | 4 976 | 3 874 |
| Net financials | 25 | 49 | 439 | 357 | 10 |
| Profit before tax | 4 201 | 3 772 | 4 962 | 5 333 | 3 884 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 4 201 | 3 772 | 4 962 | 5 333 | 3 884 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 9 296 | 9 672 | 10 451 | 11 244 | 10 427 |
| Equity | 4 739 | 4 795 | 5 278 | 5 752 | 5 253 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 557 | 4 877 | 5 173 | 5 492 | 5 175 |
| Total debt | 4 557 | 4 877 | 5 173 | 5 492 | 5 175 |
EBITDA margin
39.6%
This company
15.8%
Market median
+151% vs market
20212025
Equity ratio
50.4%
This company
38.2%
Market median
+32% vs market
20212025
Return on equity
73.9%
This company
18.4%
Market median
+302% vs market
20212025
Net profit margin
37.7%
This company
8.1%
Market median
+365% vs market
20212025
Asset turnover
0.99×
This company
1.12×
Market median
+12% vs market
20212025
Debt / equity
0.99×
This company
0.62×
Market median
+60% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EA Chief Executive Officer | Chief Executive Officer | 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2018 | |
| Chairman | 2018 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.39% | 33.39% | 2022 | |
| Company | 33.39% | 33.39% | 2022 | |
| Company | 22.57% | 22.57% | 2022 | |
| Company | 10.23% | 10.23% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Kamian As
NORMORS AS Board members of NORMORS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emil Arne Kleppe | Chief Executive Officer | 0 companies |
| Åge Magne Sandvik | Board of Directors | 0 companies |
| Malene Rødseth | Chairman | 0 companies |